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Abstract
Background: Natural products derived from various sources are being used to develop chemotherapeutic drugs. Euphorbiaceae is
widely used to treat different types of cancers. Colorectal cancer (CRC) is the second and third cause of cancer in women and men,
respectively. CRC is strongly associated with the deregulation of the Adenomatous polyposis coli (APC) gene and Poly [ADP-ribose]
polymerase (PPAR) protein.
Objectives: The current study aimed to examine the effect of doxorubicin, ethanol extract, and the flavonoid-rich fraction of Eu-
phorbia Splendida Mobayen on colon cancer HT-29 cell line death, APC gene expression, and PPAR concentration.
Methods: Following treatment of cells by Euphorbia ethanol extract, Euphorbia flavonoid-rich fraction, and doxorubicin, cell viabil-
ity assay was used to investigate the viability status of the HT-29 cell line. Total RNA was isolated from the cell line and converted
into cDNA. The expression level of the APC gene was determined by quantitative real-time PCR. Poly (ADP-ribose) polymerase (PPAR)
protein was detected by the ELIZA method.
Results: We found that Euphorbia ethanol extract, Euphorbiaflavonoid-rich fraction, and doxorubicin can stimulate dose-dependent
cell death in the HT-29 cell line, increase ACP gene expression (P = 0.001, P = 0.041, P = 0.019), and decrease PARP level (P = 0.001, P =
0.001, P = 0.001, respectively).
Conclusions: The findings indicated that doxorubicin, ethanol extract, and the flavonoid-rich fraction of Euphorbia Splendida
Mobayen had cytotoxic effects on human colon cancer HT-29 cell line by possibly stimulating apoptosis.
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1. Background
CRC is one of the most commonly diagnosed malig-
nancies that accounts for nearly 9.4% of cancers all around
the world. Its incidence is higher in developing countries
than in developed countries (1). Evidence suggests an asso-
ciation between the increased risk of cancer and nutrition
(2). A number of native plant derivatives, such as flavonoid
compounds, could suppress the cancer progression (2). It’s
confirmed that the polyphenolic structure of flavonoids
that are found abundantly in fruits and vegetables can im-
pede cancer induction in human tissues (3). Flavonoids,
such as quercetin, pinocembrin, pinostrobin, apigenin,
and galangin have antioxidant, anti-proliferative, and pro-
apoptotic properties (4). Genus Euphorbia (Euphorbiacea)
comprising only roughly 2000 species and is widespread
in Pakistan, India, and Iran. More than 82 species of the
Euphorbia are found in Iran (5). Active components of
Euphorbia species have different biological activities, in-
cluding cytotoxic, anti-tumor, antioxidant, antibacterial,
anti-inflammatory, and anti-nociceptive (6, 7). The antioxi-
dant properties of some Euphorbia species such as E. helio-
scopiaare shown (8). Euphorbia splendidaMobayen is a plant
widely distributed in the west of Iran (9). It contains diter-
penoid, triterpenoid, and flavonoid components (10). The
essential role of E. esula and E. helioscopia L (as Euphorbia
species) in impeding tumor cellular proliferation, apop-
tosis, and metastasis is shown in vitro (11, 12). The anti-
cancer properties of E. splendida on CRC cell line has not
been investigated so far. Mutations in the APC gene (a
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tumor suppressor in the Wnt signaling) can induce can-
cer, and in colorectal cancer, its levels reduce significantly
(13). Numerous studies have revealed that dysfunction
of apoptosis can cause pathogenesis and resistance to ra-
diotherapy and chemotherapeutic of cancer cells, includ-
ing CRC (14). Flavonoids might be able to prevent CRC
and cause stimulation of apoptosis following DNA dam-
age, which is an essential mechanism for cancer inhibition
(4). PARP can modify different nuclear proteins by poly
ADP-ribosylation (15). In vitro and in vivo inhibiting effects
of various flavones and flavonols as inhibitors of RARP1 are
proved (16). Since cancer cells are sensitive to inhibitors of
PARP1 (17, 18), PARP inhibitor therapy can be a new thera-
peutic option for pathological conditions such as cancers
(19).
2. Objectives
The current study aimed to compare and evaluate the
effects of EEE, EEF, doxorubicin, EEE plus doxorubicin, and
EEF plus doxorubicin combination on cell death of human
colon cancer HT-29 cell line. APC gene expression and PARP
protein level determination were studied to obtain first-
hand biological data to assess whether APC gene expres-
sion and PARP protein level changes are involved in cell
death of the HT-29 cell line after treatment with EEE, EEF,
and doxorubicin.
3. Methods
3.1. Extraction of E. splendida Extracts
Fresh aerial parts of E. splendida were collected in May
2015 from Arak, Markazi province, Iran, and then were
identified by Noori et al. (9). It was deposited under code
number CMK10 in the Herbarium of the biology depart-
ment at Arak University. The sample of the plant was dried
under shadow. The powdered materials (900 g) were ex-
tracted three times, with 90% ethanol by maceration at
room temperature. Different fractions of extract were ob-
tained by liquid-liquid fractionation, using hexane, chlo-
roform, ethyl acetate, and water. The extract and fractions
were concentrated by a rotary evaporator.
3.2. Determinationof Total FlavonoidContent of the Extract and
Fractions
TFC of E. splendida extract and fractions were estimated
using AlCl3 colorimetric assay. 20 mg of each sample
(and/or quercetin as the standard), already dissolved in
90% ethanol, was mixed with 2.5 mL of 2% AlCl3 solution
in 90% ethanol. After 40 min, the absorbance of the pro-
duced yellow solution was measured at 425 nm. TFC (as
µg quercetin equivalents/mg of sample) for each sample
was computed on the basis of a calibration curve using
quercetin: (y = 0.0169 x + 0.3526), r2 = 0.995.
3.3. Cell Culture
The tumor HT-29 cell line was obtained from the Pastor
Institute of Iran (Tehran, Iran). The cells were preserved in
a humidified atmosphere at 37ºC under 5% CO2 in a DMEM
with 10% fetal bovine serum, 1% penicillin, and strepto-
mycin. Cultures at ~ 80% confluence were routinely split
1:5 in 10 cm culture dishes, as noted in the following. The
cells were washed twice in pre-warmed PBS. Trypsin-EDTA
0.25% was added to dishes and incubated at 37ºC for 1 - 5
minutes. The cells were detached from the dishes, 1 mL pre-
warmed culture medium was added, then transferred to a
falcon tube. Cells were centrifuged at 1500 rpm and plated
in new dishes with fresh culture medium.
HT-29 cell line was harvested and seeded into 96-well
plates at a density of 10000 cells per well for further exper-
iments. Cells were counted before and after being seeded
in the 96-well plates. Cells were stained with trypan blue
and counted using neo bar lam.
3.4. Cell Viability
MTT test was performed in triplicate for both controls
and treatments. HT-29 cell line was treated with differ-
ent concentrations of 0.01, 0.1, 1, 10, 50, 100, 200, 500,
and 1000 µg/mL of EEE, EEF, doxorubicin, and combined
of EEE + doxorubicin and combined of EEF + doxorubicin
(20). To dissolve and prepare different concentrations of
the extract, DMEM was used. The control group contained
six wells for each dilution without extracts, and the wells
were kept for 24, 47, and 72 hours at 37ºC and 5% CO2 sepa-
rately. The culture medium was exchanged with an equal
volume of fresh 100 mL/L medium. In vitro, morpholog-
ical changes of cells were observed by an inverted micro-
scope after treatment. After overnight incubation, 10 µL
MTT solution was added to each well and incubated at 37ºC
and 5% CO2 for 3 hours, then 100 µL DMSO solutions was
added. The plates were placed in a shaker incubator and
shacked at 37ºC for 10 minutes. Subsequently, the optical
density (OD) of the wells was obtained at 570 nm wave-
length with a microplate reader. The mathematical meth-
ods were used to draw a dose-response relationship poly-
gon curve. Rates of cell viability were computed using the
following formula:
Cell viability inhibition rate = (average OD value of con-
trol wells - average OD value of testing wells)/average OD
value of control wells.
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3.5. PARP Assay
PARP concentration of the control and treated HT-29
cells 100 µg/mL of EEE, 1000 µg/mL of EEF, 500 µM of dox-
orubicin, (200µg/mL EEE + 200µM doxorubicin), and (500
µg/mL EEF + 500 µM doxorubicin) concentrations were
recognized using a PARP ELISA kit (Biocompare, USA) ac-
cording to the manufacturer’s instruction with an intra-
assay coefficient of variation of < 10% and an inter-assay
coefficient of variation of < 10%. HT-29 cells were seeded
overnight, treated for 24 hours, and then fixed for detach-
ing adherent cells and were analyzed. The positive and neg-
ative controls were cell culture medium and blank, respec-
tively.
3.6. Real-Time PCR Assay of APC Expression
Total RNA of the control and HT-29 cells treated with
100 µg/mL of EEE, 1000 µg/mL of EEF, 500 µM of doxoru-
bicin, (200 µg/mL EEE + 200 µM doxorubicin), and (500
µg/mL EEF + 500 µM doxorubicin) were extracted accord-
ing to manufacturer’s protocol of TRIZOL reagent (Invitro-
gen, USA). RNA was stored at -80ºC for the following quan-
titative real-time PCR. Nanodrop (ND1000) spectropho-
tometer was used to determine RNA concentrations. Total
RNA was converted to cDNA using the Quanti TectRev Tran-
scriptase kit (Qiagen, Germany).
Total RNA was reverse transcribed into cDNA accord-
ing to manufacturers’ instructions. The reaction was per-
formed in 12 µL volume containing: 4 µL of dNTP mix; 1
µL of RT Random Primers; 1 µL of MultiScribe™ Reverse
Transcriptase; 1 µL of RNase inhibitor; to 12 µL of nuclease-
free H2O and 1 µg of previously isolated RNA. The reaction
was performed in Mastercycler personal (Eppendorf, Ger-
many) with the following thermal profile:
70ºC for 5 min, 42ºC for 5 min, 70ºC for 60 min, 85ºC for
5 min.
Finally, concerning the Real-time PCR, 1 µL cDNA, 10 µL
SYBR Green PCR Master Mix, and 1 µM forward and reverse
primers were used. Specific primers used for analyzing APC
and β-actin RNA (as a housekeeping gene) (20) are shown
in Table 1. Reactions were performed on a Rotor-Gene 6000
System (Corbett, Australia) for 40 cycles (95ºC for 20 sec-
onds, 62ºC for 20 seconds, and 72ºC for 20 seconds) after
an initial incubation for 5 minutes at 95ºC. Reactions were
carried out according to the SYBR Premix Dimer Eraser kit
(TaKaRa, Shiga, Japan) protocol.
Measurements were performed in duplicate. The sin-
gle peak of the melting curve of the target gene showed
a strong specificity for the amplification. Differences in
the threshold cycle (CT) values of the target gene with cor-
responding internal control β-actin gene were calculated
(∆CT = CT gene - CT β-actin). The relative expression level
Table 1. The Sequencing of Primers
Primers Sequences Primer Length Product Size








β-actin forward 5’-AGT CTT CCT TCC
TGG GCAT-3’
19 213
β-actin reverse 5’-CAG GAG GAG
CAA TGA TCT-3’
18
of the target gene toβ-actin was described using the equa-
tion 2-∆CT.
3.7. Statistical Analysis
The graph pad prism was used to perform statistical
calculations. Data were described as mean ± SD and were
analyzed using the one-way analysis of variance (ANOVA)
and Tukey HSD post hoc test. Each experiment was tested
in triplicate. P < 0.05 was considered statistically signifi-
cant.
4. Results
4.1. Total Flavonoid Content
TFC values of E. splendid extract and fractions were pre-
sented as mean ± SD. The results are shown in Table 2.
Since EEE and EEF had the highest flavonoid content,
these were used for further investigation. Cell viability was
identified in the HT-29 cell line, which exposed the control
wells to 0.01 - 1000 µg/mL of EEE and Euphorbia ethyl ac-
etate fraction (EEF) for 24 hours of MTT test. As shown in
Figure 1A and B, EEE and EEF could cause a dose-dependent
decrease in the cell viability. The HT-29 cell viability was
reduced to 50% after treatment with 100 µg/mL of EEE
and 1000 µg/mL of EEF for 24 hours. The time course was
24, 48, and 72 hours and the ideal treatment time was 24
hours. HT-29 cell treatment with different concentrations
of doxorubicin was also investigated to evaluate the cyto-
toxic effect on HT-29 cell viability. As shown in Figure 1C,
doxorubicin-induced a remarkable cell death at a concen-
tration of 500 µM. Therefore, the 500 µM, 100, and 1000
µg/mL concentrations were identified for IC50 of doxoru-
bicin, EEE, and EEF, respectively.
According to Figure 2A and B, the HT-29 cell viability re-
duced to 50% after treatment with 200 µg/mL EEE + 200
µM doxorubicin combination and 500 µg/mL EEF + 500
µM doxorubicin combination within 24 hours.
To ensure whether EEE and EEF-induced cell death was
caused by enhanced expression of the APC gene, both
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Table 2. TFC Values of E. splendid Extract and Fractions
Extraction Ethanolic Extract Ethyl Acetate Hexanic Chloroformic Aqououes
Total flavonoid concentration 28.1 ± 0.7 mg/g 102.36 ± 0.67 mg/g 27 ± 1.7 mg/g 22.4 ± 0.6 mg/g 14.11 ± 0.5 mg/g
 
EEE Concentration (µg/ml) EEF Concentration (µg/ml) 
































































































Figure 1. Viability of treated HT-29 cells with different concentration of (A) EEE (0.01 - 1000 µg/mL), (B) EEF (0.01 - 1000 µg/mL) and (C) Doxorubicin (0.01 - 1000 µM) for 24
hours.
groups were exposed to 100 µg/mL EEE, 1000 µg/mL EEF,
500 µM doxorubicin, 200 µg/mL EEE + 200 µM doxoru-
bicin combination, and 500 µg/mL EEF + 500 µM doxoru-
bicin combination within 24 hours. The expression levels
of internal control and APC genes were determined by the
quantitative real-time PCR. As illustrated in Figure 3, APC
mRNA level of the treated HT-29 cells within 24 hours was
significantly increased compared to controls, for EEE (fold
= 2.43, P < 0.001), EEF (fold = 1.34, P < 0.041), doxorubicin
(fold = 1.42, P = 0.019), EEE-doxorubicin combination (fold
= 2.76, P < 0.001), and EEF-doxorubicin combination (fold
= 1.69, P < 0.001).
To establish whether changes in the PARP level affect
the EEE-induced loss of cell viability, the PARP level of ex-
posed HT-29 cells to EEE, EEF, doxorubicin, EEE-doxorubicin
combination, and EEF- doxorubicin combination was ex-
amined by the ELISA assay. The PARP level of HT-29 cells was
significantly decreased in the presence of 100µg/mL EEE (P
= 0.000), 1000µg/mL EEF (P < 0.001), 500µM doxorubicin
(P < 0.001), (200 µg/mL EEE + 200 µM doxorubicin) com-
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Figure 2. Viability of treated HT-29 scells with different concentration of (A) EEE (0.01 - 1000µg/mL) + doxorubicin (0.01 - 1000µM) and (B) EEF (0.01 - 1000µg/mL) + doxorubicin

















































Figure 3. APC mRNA levels of HT-29 cells in presence of 100 µg/mL of EEE, 1000
µg/mL of EEF, 500 µM of doxorubicin, (200 µg/mL EEE + 200 µM doxorubicin) and
(500 µg/mL EEF + 500 µM doxorubicin) combination for 24 hours. *P value < 0.05,
**P value < 0.001.
bination (P < 0.001), and (500 µg/mL EEF + 500 µM dox-
orubicin) combination (P < 0.001) compared to the con-
trol cells (Figure 4). The PARP level of exposed HT-29 cells




















































Figure 4. PARP levels of treated HT-29 cells in presence of 100 µg/mL of EEE, 1000
µg/mL of EEF, 500 µM of doxorubicin, (200 µg/mL EEE + 200 µM doxorubicin) and
(500µg/mL EEF + 500µM doxorubicin) combination for 24 hours. **P value < 0.001.
5. Discussion
The findings of the present study indicated decreased
cell viability after treating cells with EEE, EEF, and doxoru-
bicin. Accordingly, an inverse linear association was found
between flavonoids and the risk of developing cancer (21).
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Kern et al. suggested that polyphenolrich apple juice ex-
tract has strong EGFRinhibitory properties and an anti-
proliferative effect on HT-29 (22). Another study demon-
strated that flavonoids of red wine have positive effects
on individual human organs and methylate the biologi-
cal compounds to yield products with potentially protec-
tive effects against cancer (23). Also, the anti-cancer effects
of isoquercetin on colon cancer cells have been proved,
whereas it has no significant influence on nontumor colon
cells (24). Woo et al. reported that flavonoids can decrease
the risk of developing gastric cancer. They also reported
greater protecting effects of flavonoids in women (25).
Moreover, evidence indicates that Morus alba flavonoid ex-
tract induces dose-dependent cell death in the HT-29 cell
line (20).
The findings also showed that the PARP concentration
of cancer HT-29 cell line decreased after treatment with
EEE, EEF, and doxorubicin. EEF induced the highest de-
crease in the PARP concentration of exposed HT-29 cells. It
appears that some exposed efficient groups of EEF could
significantly induce PARP level reduction and the observed
decrease was higher compared to cells exposed to doxoru-
bicin (26).
A study showed that the PARP activity was inhibited
by natural and glucosyl flavonoids that could induce syn-
thetic lethality in BRCA mutant cells (16), which is consis-
tent with the results of the current study.
Recently, PARP1has been shown to influence the repair
of DNA and therefore, is considered as targeted therapy
(19). PARP1 expression is correlated with a cancer diagno-
sis (27). PARP1 and its product, PAR, correspond to a va-
riety of endogenous and exogenous stresses that are pro-
duced by oxidative, metabolic, and inflammatory stresses
(19). These responses can stimulate pathological condi-
tions such as cancer and autoimmune diseases. Therefore,
PARP inhibitors can be followed upon as a new therapeutic
option for such pathological conditions (19). ABT-888 (Veli-
parib), an oral PARP-1/2, is a RARP inhibitor being investi-
gated to treat different cancers (28, 29).
Ionizing radiation affects DNA structure by inducing
breaks and therefore causes severe DNA damage that leads
to cell death. To avoid such side effects, an effective dose
of radiation should be administered (30). The combined
use of radiation therapy and PARP inhibitors have a greater
impact on the tumor cells since the inhibitors stimulate
a mechanism that generates double-strand breaks in DNA
from the single-strand breaks produced by the radiother-
apy in tumor tissue with BRCA mutant. This combination
can cause a more potent therapy to target tissues while
using a similar radiation dose (31). PARP inhibitors have
various functions, and their application is not limited to
their efficiency in treating malignancies. During the past
decade, a series of functions are identified for PARP in-
hibitors that integrate the treating of other health prob-
lems such as cardiovascular diseases, stroke, metabolic dis-
orders, diabetes, and auto-immunity (32). We supposed
that reducing PARP concentration and increasing the APC
expression cause inhibitory effects on HT-29 cancer cell
growth. Therefore we intended to investigate the effect of
these compounds on APC expression and PARP level of HT-
29 cancer cells. As shown in Figure 3, all treated HT-29 cells
induced the APC level expression compared to the controls.
Increased APC expression in treated HT-29 cells can be at-
tributed to the possible anti-proliferative activity of EEE,
doxorubicin, and their combination. Accordingly, the ele-
vated APC expression level of exposed HT-29 cell to EEE was
more than those exposed to EEF, which might be related to
effects caused by other compounds of EEE such as terpens.
In 80% of CRC cases, the APC tumor suppressor gene is al-
tered (33). The effect of combined treatment with EEE and
doxorubicin on the APC expression level is greater than the
sole administration of each extract (Figure 3). It is sug-
gested that EEE can enhance the sensitivity of HT-29 cells
to doxorubicin by increasing the APC expression as a pos-
sible mechanism of inducing apoptosis and can be used as
a co-chemotherapeutic agent with doxorubicin in cancer
cell therapy.
5.1. Conclusions
Based on the findings of the current study, it can be
recommended that total extract, flavonoid-rich fraction
(ethyl acetate fraction), and doxorubicin may have cyto-
toxic effects probably through stimulating apoptosis. This
finding is valuable for identifying other chemopreventive
agents. However, further in vivo pre-clinical studies with
appropriate animal models are needed. Besides, before
clinical testing of EEE as a cancer preventive or a therapeu-
tic agent, special caution should be taken when designing
pharmacokinetics studies.
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